Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (September 2020)
23 slides from Arbutus Biopharma's investor presentation, Sep 15, 2020
Slide 1: Corporate Presentation September 2020
Corporate Presentation September 2020 NASDAQ: ABUS www.arbutusbio.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that are not historical facts are hereby identified as forward-looking statements for this pur
Slide 3: Investment Highlights
Investment Highlights Therapeutic focus – curing chronic Hepatitis B Virus (HBV) Infection Significant Team with Unmet Goal of HBV Broad Coronavirus Antiviral 16 % Medical Need Functional HBV Research Expertise & Ownership in Cure Portfolio in HBV Initiative Proven Track Genevant Record Global HBV U
Slide 4: Proven Leadership Team
Proven Leadership Team William H. Collier Michael J. Sofia, PhD Gaston Picchio, PhD President and CEO Chief Scientific Officer Chief Development Officer Successful track records in the discovery, development, and commercialization of multiple antivirals including sofosbuvir, etravirine, rilpivirine,
Slide 5: HBV Presents a Significant Unmet Medical Need
HBV Presents a Significant Unmet Medical Need >257Mpeople are chronically 15M infected with HBV, globally. Europe 2M United States 90M China ~ people900k die every year as a consequence despite the availability of effective vaccines and antivirals. : Global Hepatitis Report and Hepatitis B Fact Shee
Slide 6: Significant Opportunity to Improve HBV Cure Rates
Significant Opportunity STANDARD OF CARE THERAPIES FOR CHRONIC HBV to Improve New HBV HBV Cure Rates PegIFN Entecavir Tenofovir Therapies rate of Dosing Duration 48-weeks Chronic Chronic Undetectable HBV DNA + HBV DNA rate of Undetectable 7-19% 67-90% 76-93% HBV cures are achievable with (<60-80 IU/
Slide 7: Compelling Growth Opportunity in the HBV Market
Compelling Growth Opportunity in the HBV Market 257M chronic HBV 10.5% Diagnosed 27M An HBV curative regimen 1.8% Treated 4.5M would substantially increase diagnosisdiagnosis and treatmenttreatment rates to unlock significant Low due to sub- optimal SOC cure rate market growth opportunities. and asy
Slide 8: HBV Lifecycle Illustrates Key Points for Intervention
HBV Lifecycle Illustrates Key Points for Intervention A combination of agents with complementary MOA is needed to cure HBV 1. Nucleoside Analogue 2. Capsid Inhibitor 3. RNAi & RNA Destabilizer 2 3 1 2 NASDAQ: ABUS www.arbutusbio.com
Slide 9: Keys to Therapeutic Success
1 Reduce/Suppress 2 Reduce/Suppress Keys to Viral DNA Viral Antigens Therapeutic Block Replication Block HBsAg . NA . RNAi . Capsid Inhibitor . RNA Destabilizer Success . RNAi . RNA Destabilizer Reduce cccDNA Pool . Capsid Inhibitor Suppress HBV DNA and viral antigens Leading to an Reawaken host HBV
Slide 10: Arbutus HBV Pipeline
Arbutus HBV Pipeline Phase I Lead Optimization IND Enabling Healthy Subjects HBV Subjects Phase II HBsAg Reduction RNAi AB-729 HBV RNA Destabilizers Next Gen HBV DNA Suppression Capsid Inhibitor AB-836 Immune Reawakening PD-L1 1st gen NASDAQ: ABUS www.arbutusbio.com 10
Slide 11: AB-729 RNAi Therapeutic
AB-729 RNAi Single trigger RNAi agent targeting all HBV transcripts Therapeutic Inhibits HBV replication and lowers all HBV antigens Pan-genotypic activity across HBV genotypes Demonstrated complementarity with capsid inhibitors Proprietary GalNAc-conjugate delivery technology provides Actively targ
Slide 12: AB-729-001 Study Design
AB-729-001 Study Design Part 1: Single Ascending Part 2: Single Doses In Dose In Healthy Subjects Chronic Hepatitis B Subjects Dose 1 (60 mg) Cohort A: 180 mg n=6; 4 active : 2 placebo HBV DNA - n=6 (≥ Day 15 Safety) (≥ Day 15 Safety) Dose 2 (180 mg) Cohort B: 60 mg n=6; 4 active : 2 placebo HBV DNA
Slide 13: Comparable Mean HBsAg Declines with a Single Dose of AB-729 at Week 12
Comparable Mean HBsAg Declines with a Single 60 mg, 90 mg or 180 mg Dose of AB-729 at Week 12 AB-729 60 mg (N=6) AB-729 90 mg (N=6) AB-729 180 mg (N=4) 0.25 0.25 0 0 - 0.98 log - 0.99 log10 10 -1.23 log10 -0.25 -0.25 IU/mL IU/mL IU/mL -0.5 -0.5 -0.75 -0.75 -1 -1 -1.25 -1.25 -1.5 -1.5 0 14 28 42 56 7
Slide 14: All Subjects Responded in the Single-Dose Cohorts
All Subjects Responded in the 60 mg, 90mg and 180 mg Single-Dose Cohorts 60 mg Cohort: Minimum HBsAg decline of -0.62 log10 and maximum HBsAg decline of -2.14 log10 at week 12 90 mg Cohort: Minimum HBsAg decline of -0.79 log10 and maximum HBsAg decline of -1.87 log10 at week 12 AB-729 60 mg (N=6) AB
Slide 15: AB-729 was Generally Safe and Well Tolerated
AB-729 was Generally Safe and Well Tolerated ALT/AST levels in the 60 mg and 90 mg Single-Dose Cohorts 60 mg Single-Dose 90 mg Single-Dose Alanine Aminotransferase Aspartate Aminotransferase Alanine Aminotransferase Aspartate Aminotransferase 450 450 450 450 400 400 400 400 350 350 350 350 300 300 3
Slide 16: AB-729 Therapeutic Summary
AB-729 Continuous HBsAg declines All subjects responded to RNAi with a single 60 mg or 90 therapy with everyone mg dose through week 12 achieving at least a -0.62 log Therapeutic with mean HBsAg declines and -0.79 log reduction in of 0.99 and 1.23 log, HBsAg at week 12 in the 60 mg respectively, con
Slide 17: AB-729-001 Study
AB-729-001 Study Part 1: Single Ascending Part 2: Single Doses In Part 3: Multiple Doses In Dose In Healthy Subjects Chronic Hepatitis B Subjects Chronic Hepatitis B Subjects Dose 1 (60 mg) Cohort A: 180 mg Cohort E: 60 mg Q4W n=6; 4 active : 2 placebo HBV DNA - n=6 HBV DNA - n=7 (≥ Day 15 Safety) (
Slide 18: AB-836 Capsid Inhibitor
AB-836 Novel chemical series differentiated from AB-506 and other competitor Capsid compounds in the Class II capsid inhibitor space Inhibitor Leverages a novel binding site within the core protein dimer-dimer interface Improved intrinsic potency with EC50 < 10 nM Active against NA resistant variant
Slide 19: AB-836: A Next Generation Capsid Inhibitor
AB-836: A Next Generation Capsid Inhibitor cccDNA Formation / Human HBV DNA / 1o Mechanism 2o Mechanism Serum Shift HBV infected HBV infected Core I105T HBV infected HepDE19 (FC in EC in 40% Compound PHH HepG2-NTCP-C4 Mutation HepG2-NTCP-C4 50 (EC50 μM) Human Serum) (EC50 μM) (EC50 μM) (EC50 mM) (HB
Slide 20: Next Gen RNA Destabilizer Program
Next Gen RNA Destabilizer Program We believe Offers a novel Continuing active and this approach offers mechanism of action research for an oral to reduce HBsAg and development of potential HBsAg reducing agent other viral proteins and a next generation and all oral combination viral RNA small molecu
Slide 21: Coronavirus Strategy
Coronavirus Strategy Leveraging our proven expertise and capabilities in antiviral drug discovery and development Long term commitment Pan-coronavirus focused Small Molecule Direct-Acting Antivirals Directed Effort . nsp12 Viral Polymerase - nucleosid(t)es +RNA Virus . nsp5 Main Viral Protease - 31
Slide 22: AB-729 Clinical Collaboration with Assembly Biosciences
AB-729 Clinical Baseline Wk 24 Wk 48 Wk 72 Collaboration AB-729 + ABI-H0731 + NA with Assembly AB-729 + NA Follow Up Biosciences ABI-H0731 + NA ~60 virologically-suppressed subjects with HBeAg negative or Provides accelerated AB- HBeAg positive chronic HBV infection 729 combination proof of concept
Slide 23: Key Objectives for 2020
Key Objectives for 2020 Cash balance of $115M as July 31, 2020, cash runway into mid-2022 Objective Anticipated Timing AB-729 preliminary phase 1a/1b single-dose data Late 1Q 2020 AB-729 additional week 12 60 mg single-dose data May 2020 AB-729 week 12 single-dose 90 mg data Sep 2020 Initiate
Arbutus Biopharma — Investor Presentation (September 2020) on 6ix